GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.
Nat Rev Immunol
; 20(8): 507-514, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-613021
ABSTRACT
Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Granulocyte-Macrophage Colony-Stimulating Factor
/
Coronavirus Infections
/
Betacoronavirus
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Nat Rev Immunol
Journal subject:
Allergy and Immunology
Year:
2020
Document Type:
Article
Affiliation country:
S41577-020-0357-7
Similar
MEDLINE
...
LILACS
LIS